What happens after relapsed or refractory T-cell lymphoma? Confirming change and planning the next line

A new lump or an assessment of inadequate response can make a patient urgently search for another drug. The first task is to establish what has changed. Persistent lymphoma, recurrence after a remission, infection and treatment-related findings can require different management. Stable patients should have evidence supporting the next decision, while an organ-threatening problem needs urgent care alongside any further investigation.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

One PET focus, raised LDH or episode of fever may not independently confirm recurrent disease. Lugano response criteria help integrate lesion changes, metabolism and clinical information. If an abnormality would substantially change treatment, the team may consider image review, interval assessment or appropriate tissue evidence, taking urgency and procedural risk into account. Cheson et al.: Lugano classification for lymphoma evaluation and response
National Health Commission 2025 guidance lists the relevant relapsed or refractory PTCL uses of chidamide and golidocitinib, including previous-treatment requirements and conditional-approval or monitoring information where applicable. The hospital should check whether the individual's entity and history satisfy current requirements and confirm supply and prescribing arrangements. Marketing authorisation for a medicine does not establish approval of every combination. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布
Before travel to China, supply pathology, the complete treatment timeline, recent imaging and laboratory and organ assessments. Ask whether the receiving service can resolve a diagnostic disagreement, evaluate a different drug strategy, assess transplantation or screen for an identified trial. A statement that more new drugs exist is insufficient to judge the value or feasibility of travel.

Quick answer

Full guide

Relapsed or refractory disease is not a complete prescription. Subtype, previous medicines, length of response, recovery and treatment goals determine the next approach. Another patient's sequence after several failures should not automatically become the plan, and a known relapse does not mean that every new symptom must be caused by lymphoma.

Has the new finding established relapse?

One PET focus, raised LDH or episode of fever may not independently confirm recurrent disease. Lugano response criteria help integrate lesion changes, metabolism and clinical information. If an abnormality would substantially change treatment, the team may consider image review, interval assessment or appropriate tissue evidence, taking urgency and procedural risk into account. Cheson et al.: Lugano classification for lymphoma evaluation and response

Ask whether the conclusion is suspected or confirmed and what evidence is still missing. Recent infection and symptoms at a potentially infected site belong in the interpretation. Anxiety about waiting is understandable, but it should not lead to restarting old chemotherapy or steroids without a plan from the responsible service.

A repeat biopsy should answer a specific question

The 2025 ESMO–EHA guideline gives pathological confirmation an important role in relapse assessment. The original entity, possible changes and findings at the new site may affect the next treatment. Explain what the biopsy is expected to establish and how its result could alter management, rather than presenting it as a formality. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Tell the receiving team what original blocks and slides remain available. CAP guidance emphasises specimen quality and appropriate ancillary testing. When new tissue is needed, the team chooses a representative site with an acceptable risk. The brightest scan focus is not automatically the best target, and a painful previous biopsy should lead to discussion of the new procedure's rationale and support rather than assumptions about its necessity. CAP/ASCP: Laboratory Workup of Lymphoma in Adults guideline

If institutions use different diagnostic names, comparison of the actual material may resolve the difference. A corrected entity can change the treatment pathway more than another empirically chosen drug. Keep the review addendum with the original pathology so later teams can understand why the current approach was selected.

Reconstruct the actual treatment history

For every line, record generic drug names, dates, delivered cycles, best response, progression date and reason for discontinuation. Stopping because of infection, liver injury or neuropathy differs from proven drug resistance. A delay does not always represent a new line. The receiving clinician needs the sequence rather than only the number of regimens.

NCI lists several relapse approaches, but selection depends on exposure and tolerance. Reusing a previously active medicine, choosing treatment in the presence of neuropathy or delivering combination chemotherapy with limited marrow recovery cannot be decided from the phrase third-line therapy. Include prior transplant and radiation records as well. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

State what the next treatment is intended to achieve

Some patients are seeking control before allogeneic transplantation; others need rapid relief of an organ threat or place greater weight on avoiding repeated admission. The clinician should explain the feasible objective and how success will be measured. If treatment is called a bridge, ask what the intended destination is. The word should not conceal indefinite treatment without an agreed next step.

The EBMT Handbook discusses transplantation according to entity and disease status. Where transplant is a possible goal, early review can examine donor, organ, infection and caregiving requirements while disease treatment continues. It does not guarantee that transplantation will ultimately occur. Response and clinical condition remain part of that decision. Hübel et al.: Other B- and T-Aggressive Lymphomas, EBMT Handbook 2024

Combination chemotherapy and single agents have different contexts

Options can include salvage chemotherapy, antibody-drug conjugates, epigenetic therapies or other mechanisms. Someone who needs rapid control and can tolerate intensive treatment has different constraints from someone with slow blood-count recovery after several lines. Regimens such as ICE or DHAP appearing in NCI's summary are possible clinical pathways rather than a menu for patients to prescribe from. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

CD30-related therapy also needs the complete entity and prior exposure. If brentuximab vedotin has already been used, response and accumulated neurological problems matter to the next discussion. Persisting CD30 expression does not guarantee that repeating the drug will work. A single agent may be convenient while still causing serious infection or cytopenia; administration setting is not a simple measure of risk.

Separate established Chinese uses from research options

National Health Commission 2025 guidance lists the relevant relapsed or refractory PTCL uses of chidamide and golidocitinib, including previous-treatment requirements and conditional-approval or monitoring information where applicable. The hospital should check whether the individual's entity and history satisfy current requirements and confirm supply and prescribing arrangements. Marketing authorisation for a medicine does not establish approval of every combination. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

JACKPOT8 Part B supplies single-arm phase 2 evidence for golidocitinib in its defined relapse population. It did not randomise participants against every alternative and cannot prove an absolute ranking from its response rate. Selection also requires prevention and monitoring of infection, rather than attention only to tumour reduction. Song et al.: JACKPOT8 Part B, phase 2 golidocitinib study

The 2026 final PRIMO results report phase 2 duvelisib treatment in relapsed or refractory PTCL. Population composition, follow-up and toxicity matter to interpretation. Publication of a study is separate from approval in China or elsewhere, and access needs its own verification. A new paper does not mean a patient should change medicines immediately. Mehta-Shah et al.: Final phase 2 PRIMO duvelisib results in r/r PTCL, 2026

Ask about trials early without assuming a place is available

Trials can limit disease entity, previous treatment, organ function and other conditions, and may require fresh tissue or a particular marker. NCI explains screening, consent and study phases. A recruitment listing does not confirm an available place at a specific hospital or establish eligibility after an initial record review. NCI: How Clinical Trials Work

Use a trial identifier and a real study site to ask which decisive criteria can be checked first, who manages the disease during screening and what happens if enrolment fails. Do not independently stop needed treatment to satisfy an online washout requirement. Clinical and research teams must coordinate washout or bridging. Patients should understand known hazards, remaining uncertainty and care after withdrawal.

Transplant opportunity depends on the current state

The 2026 EBMT analysis of major T-cell entities provides information about allogeneic transplantation in clinical practice, including the characteristics of patients able to reach it. Those results cannot promise the same outcome to every relapsed patient, and finding a donor does not by itself establish that transplantation should happen immediately. EBMT Lymphoma Working Party: allogeneic transplantation for major T-cell lymphoma entities, 2026

NCI distinguishes transplant sources, recovery and complications. Ask whether disease needs further control, whether infection is sufficiently stable, why a donor is being considered and where follow-up will occur. Previous mogamulizumab and other relevant drug exposure must be communicated because it may affect subsequent transplant risk. NCI: Stem Cell Transplants in Cancer Treatment DailyMed: POTELIGEO mogamulizumab prescribing information, February 2026

If transplantation is unsuitable, the team should still explain the next medicine, trial or symptom-management plan. Being ineligible for one intervention should not leave continuing care undefined. Patients can weigh possible control, admission burden and personal preferences rather than treat transplantation as a test they must pass.

Protect the ability to receive treatment

After several lines, immunosuppression and delayed count recovery may create additional vulnerability. Fever, cough or new breathlessness needs timely assessment. NCI's infection information cautions against interpreting temporary improvement after fever treatment as proof of safety. While another opinion is pending, the original team or local urgent service still needs to manage current problems; remote document review cannot replace examination. NCI: Infection and Neutropenia during Cancer Treatment

Poor intake, a painful mouth and persistent diarrhoea can reduce strength and treatment feasibility. Report them and request support. Palliative care can run alongside salvage treatment, addressing symptoms and caregiving burden. NCI makes clear that it is not restricted to people who have stopped anticancer medicines. Accepting symptom support does not undermine an intention to pursue further treatment. NCI: Palliative Care in Cancer

Make an international second opinion about a concrete decision

Before travel to China, supply pathology, the complete treatment timeline, recent imaging and laboratory and organ assessments. Ask whether the receiving service can resolve a diagnostic disagreement, evaluate a different drug strategy, assess transplantation or screen for an identified trial. A statement that more new drugs exist is insufficient to judge the value or feasibility of travel.

If disease is changing quickly, the teams should establish who continues treatment while arrangements are pending and what developments should suspend travel. Stabilisation takes priority over a fixed arrival date. Return the written second opinion to the existing team so that any new treatment and local support can be coordinated, rather than making the patient the sole messenger carrying decisions between institutions.

After the consultation, retain one current plan showing the next intervention, the reason for it and the date or clinical condition for reassessment. Superseded suggestions can remain in the file as history, clearly identified as such. This avoids restarting an abandoned regimen merely because an older letter is the first page a clinician sees during an urgent visit.